By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

While participants on a lower dose of Wave Life Sciences’ RNA therapy lost 5.3% total fat at the six-month mark, those ...

Scientists at City of Hope and TGen (part of City of Hope) are the first to explain a major mechanism for why gaining excess ...

Novo Nordisk A/S is doubling down on obesity and diabetes, putting it at loggerheads with investors calling for the Danish ...

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

It's not much of a contest right now.

On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.

For parents of a child with obesity, a normal lab report from the pediatrician may suggest that their weight isn’t yet a ...

The drugmaker said UBT251 achieved mean body weight reduction of up to 9.8% after a 24-week trial.

Childhood obesity increases cardiometabolic risk even in “healthy” cases. Early treatment may reduce long-term disease burden. Find out more.

A new report suggests patients with obesity and chronic spontaneous urticaria (CSU) tend to be older when diagnosed with the latter condition, and are also less likely to respond to omalizumab (Xolair ...